A Randomized, Multiple Dose, Double Blind, 5-Way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine - Full Text View

Sponsor:	Faes Farma, S.A.
Information provided by:	Faes Farma, S.A.
ClinicalTrials.gov Identifier:	NCT00419783

Purpose

The purpose of this study is to evaluate the effect of two doses of bilastine (20 and 100 mg) compared to bilastine 20 mg administered with ketoconazole 400 mg, moxifloxacin 400 mg, and placebo. Subjects will receive each of the five study treatments in a crossover fashion administered once daily for 4 days.

Condition	Intervention	Phase
Healthy	Drug: bilastine Drug: Bilastine Drug: Bilastine & Ketoconazole Drug: Moxifloxacin Drug: Placebo	Phase I

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Crossover Assignment, Safety Study
Official Title:	A Phase 1, Randomized, Multiple Dose, Double Blind, 5-Way Crossover Study of the Electrocardiographic Effects of Bilastine in Healthy Adult Subjects

Resource links provided by NLM:

Drug Information available for: Ketoconazole Fungarest Moxifloxacin Moxifloxacin hydrochloride Bilastine

U.S. FDA Resources

Further study details as provided by Faes Farma, S.A.:

Primary Outcome Measures:

QTc Interval prolongation [ Time Frame: 4 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

vital signs, adverse events, and routine clinical laboratory tests [ Time Frame: 4 days ] [ Designated as safety issue: Yes ]

Enrollment:	30
Study Start Date:	August 2006
Study Completion Date:	December 2006
Primary Completion Date:	December 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Bilastine 20 mg	Drug: bilastine 20 mg tablets.
2: Experimental Bilastine 100 mg	Drug: Bilastine 100 mg (5 tablets of 20 mg)
3: Active Comparator Bilastine 20 mg + Ketoconazole 400 mg	Drug: Bilastine & Ketoconazole 1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
4: Active Comparator Moxifloxacin 400 mg	Drug: Moxifloxacin 1 capsule containing moxifloxacin 400 mg tablet
5: Placebo Comparator Placebo	Drug: Placebo Placebo tablets

Detailed Description:

This is a single center, Phase 1 study that utilizes a randomized, multiple-dose, double-blind, 5-way crossover design with a placebo control and two active controls. A minimum seven day washout period following four days of dosing for each of the five treatments.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy subjects with no clinically significant findings note on screening assessments including medical history, physical examination and laboratory results

Exclusion Criteria:

Clinically significant medical condition
Clinically significant history of ECG abnormalities or family history of QTc interval syndrome
Use of tobacco and/or nicotine products >3 months prior to screening
Use of any prescription medications within 14 days prior to screening
Use of over the counter medications (including herbal products) within 7 days prior to screening

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00419783

Locations

United States, Arizona
MDS Pharma Services
Phoenix, Arizona, United States, 85044

Sponsors and Collaborators

Faes Farma, S.A.

Investigators

Principal Investigator:

Mark J Allison, MD

MDS Pharma Services (US)

More Information

No publications provided

Study ID Numbers:	459-09, BILA-459/09, AA24101
Study First Received:	January 8, 2007
Last Updated:	January 9, 2009
ClinicalTrials.gov Identifier:	NCT00419783 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Faes Farma, S.A.:

Allergic rhinitis
Urticaria

Additional relevant MeSH terms:

Anti-Infective Agents
Moxifloxacin
Therapeutic Uses

Antifungal Agents
Ketoconazole
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010